Progress and challenges in viral vector manufacturing

Human Molecular Genetics

Volumn 25, Issue R1, 2016, Pages R42-R52

  van der Loo, Johannes C M ^a   Wright, J Fraser ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b Ophthalmology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; BLOOD CLOTTING FACTOR 9; CALCIUM PHOSPHATE; CD34 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 2; LIPOPROTEIN LIPASE; POLYETHYLENEIMINE; TRIACYLGLYCEROL LIPASE; VIRUS VECTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; BACULOVIRIDAE; BHK-21 CELL LINE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; ELECTROPORATION; GENE REPLACEMENT THERAPY; GENE THERAPY; GENETIC TRANSFECTION; GOOD MANUFACTURING PRACTICE; HEK293 CELL LINE; HEMATOLOGIC MALIGNANCY; HEMOPHILIA B; HUMAN; HUMAN ALPHAHERPESVIRUS 1; HYPERLIPOPROTEINEMIA TYPE 1; INVESTMENT; LEBER CONGENITAL AMAUROSIS; LENTIVIRUS; LONG TERMINAL REPEAT; MUTAGENESIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PIPELINE; PLASMID; QUALITY CONTROL; RETINA PIGMENT CELL; REVIEW; SF9 CELL LINE; STOICHIOMETRY; T LYMPHOCYTE; VERO CELL LINE; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; CELL LINE; CLINICAL TRIAL (TOPIC); GENE VECTOR; LICENSING;

CELL LINE; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LICENSURE; QUALITY CONTROL; TRANSFECTION;

EID: 84976453525     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddv451     Document Type: Review

References (126)

1. Edelstein, M. The Journal of Gene Medicine Clinical Trial site. Gene Therapy Clinical Trials Worldwide. http://www.wiley.com//legacy/wileychi/genmed/clinical/. (October 2015, date last accessed).
2. Herper, M. (2014) Gene Therapy’s Big Comeback. In: Forbes, April 14. http://www.forbes.com/sites/matthewherper/2014/03/26/once-seen-as-too-scary-editing-peoples-genes-withviruses-makes-a-618-million-comeback/ (October 2015, date last accessed).
3. Philippidis, A. (2014) Gene therapy briefs. Hum. Gene. Ther., 25, 262–264.
4. Chaudhary, G. (2015) Gene therapy market to be worth over USD 10 Billion by 2025, Predicts Roots Analysis. Business Wire, London. March 3, 2015.
5. Roots Analysis. (2015) Gene therapy market, 2015–2025.
6. Yla-Herttuala, S. (2012) Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther., 20, 1831–1832.
7. Peng, Z. (2005) Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene. Ther., 16, 1016–1027.
8. Liang, M. (2012) Clinical development of oncolytic viruses in China. Curr. Pharm. Biotechnol., 13, 1852–1857.
9. Gordon, E.M. and Hall, F.L. (2010) Rexin-G, a targeted genetic medicine for cancer. Expert. Opin. Biol. Ther., 10, 819–832.
10. Human Stem Cells Institute (2011) HSCI receives approval to market neovasculgen – the first Russian gene-therapy drug for treatment of peripheral arterial disease. Human Stem Cells Institute, Moscow, Russia. December 7, 2011.
11. Spark Therapeutics (2015) Spark therapeutics announces positive top-line results from pivotal Phase 3 Trial of SPKRPE65 for genetic blinding conditions. Globe Newswire, Philadelphia, PA. October 5, 2015.
12. Schimmer, J. and Breazzano, S. (2015) Investor outlook: focus on upcoming LCA2 gene therapy Phase III results. Hum. Gene. Ther. Clin. Dev., 26, 144–149.
13. Huggett, B. (2014) Innovative startups 2013. Nat. Biotechnol., 32, 127.
14. Rogers, G.L. and Herzog, R.W. (2015) Gene therapy for hemophilia. Front. Biosci. (Landmark Ed)., 20, 556–603.
15. Herzog, R.W., Yang, E.Y., Couto, L.B., Hagstrom, J.N., Elwell, D., Fields, P.A., Burton, M., Bellinger, D.A., Read, M.S., Brinkhous, K.M. et al. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med., 5, 56–63.
16. Herzog, R.W., Hagstrom, J.N., Kung, S.H., Tai, S.J., Wilson, J. M., Fisher, K.J. and High, K.A. (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc. Natl Acad. Sci. USA., 94, 5804–5809.
17. Snyder, R.O., Miao, C.H., Patijn, G.A., Spratt, S.K., Danos, O., Nagy, D., Gown, A.M., Winther, B., Meuse, L., Cohen, L.K. et al. (1997) Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet., 16, 270–276.
18. Manno, C.S., Chew, A.J., Hutchison, S., Larson, P.J., Herzog, R.W., Arruda, V.R., Tai, S.J., Ragni, M.V., Thompson, A., Ozelo, M. et al. (2003) AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood., 101, 2963–2972.
19. Jiang, H., Pierce, G.F., Ozelo, M.C., de Paula, E.V., Vargas, J.A., Smith, P., Sommer, J., Luk, A., Manno, C.S., High, K.A. et al. (2006) Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther., 14, 452–455.
20. Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B. et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12, 342–347.
21. Patel, N., Reiss, U., Davidoff, A.M. and Nathwani, A.C. (2014) Progress towards gene therapy for haemophilia B. Int. J. Hematol., 99, 372–376.
22. Nathwani, A.C., Nienhuis, A.W. and Davidoff, A.M. (2014) Our journey to successful gene therapy for hemophilia B. Hum. Gene. Ther., 25, 923–926.
23. Nathwani, A.C., Tuddenham, E.G., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D.C., Chowdary, P., Riddell, A., Pie, A.J., Harrington, C. et al. (2011) Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365, 2357–2365.
24. Nathwani, A.C., Reiss, U.M., Tuddenham, E.G., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D. et al. (2014) Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N. Engl. J. Med., 371, 1994–2004.
25. Cideciyan, A.V., Jacobson, S.G., Beltran, W.A., Sumaroka, A., Swider, M., Iwabe, S., Roman, A.J., Olivares, M.B., Schwartz, S.B., Komaromy, A.M. et al. (2013) Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl Acad. Sci. USA, 110, E517–E525.
26. Testa, F., Maguire, A.M., Rossi, S., Pierce, E.A., Melillo, P., Marshall, K., Banfi, S., Surace, E.M., Sun, J., Acerra, C. et al. (2013) Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology, 120, 1283–1291.
27. Bainbridge, J.W., Mehat, M.S., Sundaram, V., Robbie, S.J., Barker, S.E., Ripamonti, C., Georgiadis, A., Mowat, F.M., Beat-tie, S.G., Gardner, P.J. et al. (2015) Long-term effect of gene therapy on Leber’s congenital amaurosis. N. Engl. J. Med., 372, 1887–1897.
28. Maguire, A.M., Simonelli, F., Pierce, E.A., Pugh, E.N. Jr., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K.A., Testa, F., Surace, E.M. et al. (2008) Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N. Engl. J. Med., 358, 2240–2248.
29. Bennicelli, J., Wright, J.F., Komaromy, A., Jacobs, J.B., Hauck, B., Zelenaia, O., Mingozzi, F., Hui, D., Chung, D., Rex, T.S. et al. (2008) Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol. Ther., 16, 458–465.
30. Hacein-Bey-Abina, S., Pai, S.Y., Gaspar, H.B., Armant, M., Berry, C.C., Blanche, S., Bleesing, J., Blondeau, J., de Boer, H., Buckland, K.F. et al. (2014) A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N. Engl. J. Med., 371, 1407–1417.
31. Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E. et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415–419.
32. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M.H., Pike-Overzet, K., Chatters, S.J., de Ridder, D. et al. (2008) Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118, 3143–3150.
33. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K. et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118, 3132–3142.
34. Thornhill, S.I., Schambach, A., Howe, S.J., Ulaganathan, M., Grassman, E., Williams, D., Schiedlmeier, B., Sebire, N.J., Gaspar, H.B., Kinnon, C. et al. (2008) Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther., 16, 590–598.
35. van der Loo, J.C., Swaney, W.P., Grassman, E., Terwilliger, A., Higashimoto, T., Schambach, A., Baum, C., Thrasher, A.J., Williams, D.A., Nordling, D.L. et al. (2012) Scale-up and manufacturing of clinical-grade self-inactivating gamma-retroviral vectors by transient transfection. Gene. Ther., 19, 246–254.
36. van der Loo, J.C., Swaney, W.P., Grassman, E., Terwilliger, A., Higashimoto, T., Schambach, A., Hacein-Bey-Abina, S., Nordling, D.L., Cavazzana-Calvo, M., Thrasher, A.J. et al. (2012) Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency. Gene. Ther., 19, 872–876.
37. Pai, S.Y., Logan, B.R., Griffith, L.M., Buckley, R.H., Parrott, R.E., Dvorak, C.C., Kapoor, N., Hanson, I.C., Filipovich, A.H., Jyonouchi, S. et al. (2014) Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N. Engl. J. Med., 371, 434–446.
38. Touzot, F., Moshous, D., Creidy, R., Neven, B., Frange, P., Cros, G., Caccavelli, L., Blondeau, J., Magnani, A., Luby, J.M. et al. (2015) Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1. Blood, 125, 3563–3569.
39. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med., 365, 725–733.
40. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A. and June, C.H. (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 95ra73.
41. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., Maric, I., Stetler-Stevenson, M., Phan, G.Q., Hughes, M.S., Sherry, R.M. et al. (2012) B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood, 119, 2709–2720.
42. Brentjens, R.J., Riviere, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S., Borquez-Ojeda, O. et al. (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118, 4817–4828.
43. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F. et al. (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 1509–1518.
44. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cow-ell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M. et al. (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 177ra138.
45. Gill, S. and June, C.H. (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev., 263, 68–89.
46. Merten, O.-W., Schweizer, M., Chahal, P. and Kamen, A.A. (2014) Manufacturing of viral vectors for gene therapy: part I. Upstream processing. Pharm. Bioprocess, 2, 183–203.
47. Merten, O.W. (2004) State-of-the-art of the production of retroviral vectors. J. Gene. Med., 6(Suppl 1), S105–S124.
48. Kutner, R.H., Puthli, S., Marino, M.P. and Reiser, J. (2009) Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC. Biotechnol., 9, 10.
49. Wright, J.F., Wellman, J. and High, K.A. (2010) Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr. Gene. Ther., 10, 341–349.
50. Liu, Y.L., Wagner, K., Robinson, N., Sabatino, D., Margaritis, P., Xiao, W. and Herzog, R.W. (2003) Optimized production of high-titer recombinant adeno-associated virus in roller bottles. Biotechniques, 34, 184–189.
51. Cornetta, K., Matheson, L. and Ballas, C. (2005) Retroviral vector production in the National Gene Vector Laboratory at Indiana University. Gene. Ther., 12(Suppl 1), S28–S35.
52. Geraerts, M., Michiels, M., Baekelandt, V., Debyser, Z. and Gijsbers, R. (2005) Upscaling of lentiviral vector production by tangential flow filtration. J. Gene. Med., 7, 1299–1310.
53. Karolewski, B.A., Watson, D.J., Parente, M.K. and Wolfe, J.H. (2003) Comparison of transfection conditions for a lentivirus vector produced in large volumes. Hum. Gene. Ther., 14, 1287–1296.
54. Merten, O.W., Charrier, S., Laroudie, N., Fauchille, S., Dugue, C., Jenny, C., Audit, M., Zanta-Boussif, M.A., Chautard, H., Radrizzani, M. et al. (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum. Gene. Ther., 22, 343–356.
55. Slepushkin, V., Chang, N., Cohen, R., Gan, Y., Jiang, B., Deausen, E., VBerlinger, D., Binder, G., Andre, K., Hummeau, L. et al. (2003) Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocessing. J., 2, 89–95.
56. Przybylowski, M., Hakakha, A., Stefanski, J., Hodges, J., Sadelain, M. and Riviere, I. (2006) Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories. Gene. Ther., 13, 95–100.
57. Lock, M., Alvira, M., Vandenberghe, L.H., Samanta, A., Toelen, J., Debyser, Z. and Wilson, J.M. (2010) Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum. Gene. Ther., 21, 1259–1271.
58. Nasimuzzaman, M., Lynn, D., Beuerlein, M., Cross, S., Link, K., Lutzko, C.M., Nordling, D.L., Russell, D.W., Malik, P. and van der Loo, J.C.M. (2015) Scale-up and manufacturing of high-titer foamy virus vector containing human CD18 for the treatment of leukocyte adhesion deficiency. Poster 461, In American Society of Gene & Cell Therapy, New Orleans, LA, May 13–16, 2015.
59. Nasimuzzaman, M., Kim, Y.S., Wang, Y.D. and Persons, D.A. (2014) High-titer foamy virus vector transduction and integration sites of human CD34(+) cell-derived SCIDrepopulating cells. Mol. Ther. Methods. Clin. Dev., 1, 14020.
60. Lesch, H.P., Heikkila, K.M., Lipponen, E.M., Valonen, P., Muller, A., Rasanen, E., Tuunanen, T., Hassinen, M.M., Parker, N., Karhinen, M. et al. (2015) Process development of adenoviral vector production in fixed bed bioreactor: from bench to commercial scale. Hum. Gene. Ther., 26, 560–571.
61. Emmerling, V.V., Pegel, A., Milian, E.G., Venereo-Sanchez, A., Kunz, M., Wegele, J., Kamen, A.A., Kochanek, S. and Hoerer, M. (2015) Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells. Biotechnol. J., doi: 10.1002/ biot.201500176.
62. Wang, X., Olszewska, M., Qu, J., Wasielewska, T., Bartido, S., Hermetet, G., Sadelain, M. and Riviere, I. (2015) Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J. Immunother., 38, 127–135.
63. Valkama, A.J., Lesch, H.P., Martikainen, A., Malinen, J., Salonen, T., Mahonen, M., Heikura, T. and Yla-Herttuala, S. (2015) Optimization of lentiviral vector production in a fixed-bed bioreactor. In European Society of Gene and Cell Therapy, Vol. P155.
64. Wu, S.C., Huang, G.Y. and Liu, J.H. (2002) Production of retrovirus and adenovirus vectors for gene therapy: a comparative study using microcarrier and stationary cell culture. Biotechnol. Prog., 18, 617–622.
65. Pizzato, M., Merten, O.W., Blair, E.D. and Takeuchi, Y. (2001) Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. Gene. Ther., 8, 737–745.
66. Rourou, S., van der Ark, A., Majoul, S., Trabelsi, K., van der Velden, T. and Kallel, H. (2009) A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor. Appl. Microbiol. Biotechnol., 85, 53–63.
67. Virag, T., Cecchini, S. and Kotin, R.M. (2009) Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum. Gene. Ther., 20, 807–817.
68. Cecchini, S., Negrete, A. and Kotin, R.M. (2008) Toward exascale production of recombinant adeno-associated virus for gene transfer applications. Gene. Ther., 15, 823–830.
69. Cecchini, S., Virag, T. and Kotin, R.M. (2011) Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. Hum. Gene. Ther., 22, 1021–1030.
70. Urabe, M., Ding, C. and Kotin, R.M. (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene. Ther., 13, 1935–1943.
71. Negrete, A. and Kotin, R.M. (2007) Production of recombinant adeno-associated vectors using two bioreactor configurations at different scales. J. Virol. Methods, 145, 155–161.
72. Kotin, R.M. (2011) Large-scale recombinant adeno-associated virus production. Hum. Mol. Genet., 20, R2–R6.
73. Segura, M.M., Garnier, A., Durocher, Y., Ansorge, S. and Kamen, A. (2010) New protocol for lentiviral vector mass production. Methods. Mol. Biol., 614, 39–52.
74. Ansorge, S., Lanthier, S., Transfiguracion, J., Durocher, Y., Henry, O. and Kamen, A. (2009) Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures. J. Gene. Med., 11, 868–876.
75. Merten, O.W., Cruz, P.E., Rochette, C., Geny-Fiamma, C., Bouquet, C., Goncalves, D., Danos, O. and Carrondo, M.J. (2001) Comparison of different bioreactor systems for the production of high titer retroviral vectors. Biotechnol. Prog., 17, 326–335.
76. Wikstrom, K., Blomberg, P. and Islam, K.B. (2004) Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy. Biotechnol. Prog., 20, 1198–1203.
77. Ozuer, A., Wechuck, J.B., Goins, W.F., Wolfe, D., Glorioso, J.C. and Ataai, M.M. (2002) Effect of genetic background and culture conditions on the production of herpesvirus-based gene therapy vectors. Biotechnol. Bioeng., 77, 685–692.
78. Palfi, S., Gurruchaga, J.M., Ralph, G.S., Lepetit, H., Lavisse, S., Buttery, P.C., Watts, C., Miskin, J., Kelleher, M., Deeley, S. et al. (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. Lancet, 383, 1138–1146.
79. Greene, M.R., Lockey, T., Mehta, P.K., Kim, Y.S., Eldridge, P.W., Gray, J.T. and Sorrentino, B.P. (2012) Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line. Hum. Gene. Ther. Methods., 23, 297–308.
80. Grieger, J.C., Soltys, S.M. and Samulski, R.J. (2015) Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol. Ther., doi: 10.1038/mt.2015.187.
81. Thorne, B.A., Takeya, R.K. and Peluso, R.W. (2009) Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum. Gene. Ther., 20, 707–714.
82. Farson, D., Harding, T.C., Tao, L., Liu, J., Powell, S., Vimal, V., Yendluri, S., Koprivnikar, K., Ho, K., Twitty, C. et al. (2004) Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. J. Gene. Med., 6, 1369–1381.
83. Thomas, D.L., Wang, L., Niamke, J., Liu, J., Kang, W., Scotti, M.M., Ye, G.J., Veres, G. and Knop, D.R. (2009) Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum. Gene. Ther., 20, 861–870.
84. Segura, M.M., Garnier, A., Durocher, Y., Coelho, H. and Kamen, A. (2007) Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification. Biotechnol. Bioeng., 98, 789–799.
85. Durocher, Y., Pham, P.L., St-Laurent, G., Jacob, D., Cass, B., Chahal, P., Lau, C.J., Nalbantoglu, J. and Kamen, A. (2007) Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J. Virol. Methods., 144, 32–40.
86. Park, J.Y., Lim, B.P., Lee, K., Kim, Y.G. and Jo, E.C. (2006) Scalable production of adeno-associated virus type 2 vectors via suspension transfection. Biotechnol. Bioeng., 94, 416–430.
87. Titus, K., Klimovich, V., Rothenberg, M., Pardo, P., Tanner, A. and Martin, G. (2010) Closed system cell culture protocol using HYPERStack vessels with gas permeable material technology. J. Vis. Exp., doi: 10.3791/2499.
88. Qu, G., Bahr-Davidson, J., Prado, J., Tai, A., Cataniag, F., McDonnell, J., Zhou, J., Hauck, B., Luna, J., Sommer, J.M. et al. (2007) Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J. Virol. Methods., 140, 183–192.
89. Throm, R.E., Ouma, A.A., Zhou, S., Chandrasekaran, A., Lockey, T., Greene, M., De Ravin, S.S., Moayeri, M., Malech, H.L., Sorrentino, B.P. et al. (2009) Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood, 113, 5104–5110.
90. Guy, H.M., McCloskey, L., Lye, G.J., Mitrophanous, K.A. and Mukhopadhyay, T.K. (2013) Characterization of lentiviral vector production using microwell suspension cultures of HEK293T-derived producer cells. Hum. Gene. Ther. Methods, 24, 125–139.
91. Graham, F.L. and van der Eb, A.J. (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52, 456–467.
92. Pear, W.S., Nolan, G.P., Scott, M.L. and Baltimore, D. (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl Acad. Sci. USA, 90, 8392–8396.
93. Galibert, L. and Merten, O.W. (2011) Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. J. Invertebr. Pathol., 107(Suppl), S80–S93.
94. Segura, M.M., Mangion, M., Gaillet, B. and Garnier, A. (2013) New developments in lentiviral vector design, production and purification. Expert. Opin. Biol. Ther., 13, 987–1011.
95. Lee, J.H. and Welsh, M.J. (1999) Enhancement of calcium phosphate-mediated transfection by inclusion of adenovirus in coprecipitates. Gene. Ther., 6, 676–682.
96. Chen, C. and Okayama, H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol., 7, 2745–2752.
97. Chen, C.A. and Okayama, H. (1988) Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA. Biotechniques, 6, 632–638.
98. Tognon, M., Cattozzo, E.M., Bianchi, S. and Romanelli, M.G. (1996) Enhancement of HSV-DNA infectivity, in Vero and RS cells, by a modified calcium-phosphate transfection technique. Virus. Genes., 12, 193–197.
99. Ma, B., Zhang, S., Jiang, H., Zhao, B. and Lv, H. (2007) Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J. Control. Release., 123, 184–194.
100. Nguyen, L.T., Atobe, K., Barichello, J.M., Ishida, T. and Kiwada, H. (2007) Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol. Pharm. Bull., 30, 751–757.
101. Kuroda, H., Kutner, R.H., Bazan, N.G. and Reiser, J. (2009) Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J. Virol. Methods., 157, 113–121.
102. Hildinger, M., Baldi, L., Stettler, M. and Wurm, F.M. (2007) High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells. Biotechnol. Lett., 29, 1713–1721.
103. Feng, L., Guo, M., Zhang, S., Chu, J., Zhuang, Y. and Zhang, S. (2008) Improvement in the suspension-culture production of recombinant adeno-associated virus-LacZ in HEK-293 cells using polyethyleneimine-DNA complexes in combination with hypothermic treatment. Biotechnol. Appl. Biochem., 50, 121–132.
104. Li, L.H., Shivakumar, R., Feller, S., Allen, C., Weiss, J.M., Dzekunov, S., Singh, V., Holaday, J., Fratantoni, J. and Liu, L.N. (2002) Highly efficient, large volume flow electroporation. Technol. Cancer. Res. Treat., 1, 341–350.
105. Broussau, S., Jabbour, N., Lachapelle, G., Durocher, Y., Tom, R., Transfiguracion, J., Gilbert, R. and Massie, B. (2008) Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther., 16, 500–507.
106. Ikeda, Y., Takeuchi, Y., Martin, F., Cosset, F.L., Mitrophanous, K. and Collins, M. (2003) Continuous high-titer HIV-1 vector production. Nat. Biotechnol., 21, 569–572.
107. Sanber, K.S., Knight, S.B., Stephen, S.L., Bailey, R., Escors, D., Minshull, J., Santilli, G., Thrasher, A.J., Collins, M.K. and Takeuchi, Y. (2015) Construction of stable packaging cell lines for clinical lentiviral vector production. Sci. Rep., 5, 9021.
108. Hu, P., Li, Y., Sands, M.S., McCown, T. and Kafri, T. (2015) Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors. Mol. Ther. Methods. Clin. Dev., 2, 15025.
109. Stornaiuolo, A., Piovani, B.M., Bossi, S., Zucchelli, E., Corna, S., Salvatori, F., Mavilio, F., Bordignon, C., Rizzardi, G.P. and Bovolenta, C. (2013) RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. Hum. Gene. Ther. Methods., 24, 228–240.
110. Wright, J.F. (2009) Transient transfection methods for clinical adeno-associated viral vector production. Hum. Gene. Ther., 20, 698–706.
111. Smith, R.H., Levy, J.R. and Kotin, R.M. (2009) A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol. Ther., 17, 1888–1896.
112. Wright, J.F. (2011) Adeno-associated viral vector manufacturing: keeping pace with accelerating clinical development. Hum. Gene. Ther., 22, 913–914.
113. Chulay, J.D., Ye, G.J., Thomas, D.L., Knop, D.R., Benson, J.M., Hutt, J.A., Wang, G., Humphries, M. and Flotte, T.R. (2011) Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum. Gene. Ther., 22, 155–165.
114. Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A. and Chapman, M.S. (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl Acad. Sci USA, 99, 10405–10410.
115. Wright, J.F. and Zelenaia, O. (2011) Vector characterization methods for quality control testing of recombinant adeno-associated viruses. Methods. Mol. Biol., 737, 247–278.
116. FDA. (2008) Guidance for industry. Potency tests for cellular and gene therapy products. Draft guidance. Center Biologics Eval. Res. http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/ CellularandGeneTherapy/ucm072571.htm.
117. Hauck, B., Murphy, S.L., Smith, P.H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J.M., High, K.A. and Wright, J.F. (2009) Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol. Ther., 17, 144–152.
118. Chadeuf, G., Ciron, C., Moullier, P. and Salvetti, A. (2005) Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol. Ther., 12, 744–753.
119. Dolgin, E. (2012) Gene therapies advance, but some see manufacturing challenges. Nat. Med., 18, 1718–1719.
120. World Health Organization. (1998) Requirements for the use of animal cells as in vitro substrates for the production of biologicals (Requirement for Biological substance No. 50). WHO Expert Committee on Biological Standardization, Annex 1 (WHO Technical Report Series, No. 878), Geneva.
121. Wright, J.F. (2014) Product-related impurities in clinical-grade recombinant AAV vectors: Characterization and risk assessment. Biomedicines, 2, 80–97.
122. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). (2012) Assessment report: Glybera (Procedure No. EMEA/H/C/002145), European Medicines Agency, Geneva.
123. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) and Office of Regulatory Affairs (ORA). (2008) Guidance for industry: CGMP for Phase 1 Investigational Drugs. FDA, USA.
124. International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. (2000) ICH harmonised tripartite guideline: Good manufacturing practice guide for active pharmaceutical ingredients. Q7. European Medicines Agency.
125. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER). (2001) Guidance for industry: Q7A good manufacturing practice guidance for active pharmaceutical ingredients. FDA, USA.
126. FDA. (2015) 21 CFR 11 Electronic records; Electronic Signatures. Code of Federal Regulations Title 21 – Food and Drugs. FDA, USA.